Stock Comparison
PFE vs SMMT
Pfizer Inc vs Summit Therapeutics Inc
Who's the better investment? Let's break it down.
The Verdict
SMMT takes this one.
It's not even close. SMMT outscores PFE by 4.7 points. That's a significant gap in our deep value framework.
Want to compare any two stocks?
Sign up free — get 3 DVR analyses/day, 1800+ stocks, portfolio roast. No credit card.
Valuation
PFE
Metric
SMMT
Market Cap
P/E Ratio
Lower may indicate better value
Forward P/E
Price/Book
EV/EBITDA
Profitability & Growth
PFE
Metric
SMMT
Profit Margin
Gross Margin
Operating Margin
Return on Equity
Return on Assets
Revenue Growth
EPS
Financial Health
PFE
Metric
SMMT
Debt-to-Equity
Lower = less leverage
Current Ratio
Above 1.0 is healthy
Beta
Lower = less volatile
Dividend Yield
Risk Comparison
PFE
What Could Go Wrong
The biggest risk for Pfizer is the ongoing and accelerated erosion of revenue from key patent expirations and declining COVID-related product sales (Paxlovid/Comirnaty). If the pipeline of new product...
Red Flags
- 🚩Adjusted EPS declined -18% YoY in Q1 2026 despite revenue beat, indicating continued margin pressure...
- 🚩High reliance on successful pipeline execution to offset significant revenue declines from mature pr...
- 🚩Market Cap ($146.42B) requires an unrealistic 10x growth to over $1.4 trillion in 3-5 years, a scale...
SMMT
Competitive Moat
PFE
Rating
🛡️ Wide
Trend
➡️ Stable
SMMT
Rating
🛡️ Narrow
Trend
📈 Expanding
Investment Thesis
If Pfizer's non-COVID product portfolio (e.g., Vyndaqel, Eliquis, newly launched oncology/rare disease drugs) continues to deliver mid-single-digit operational growth (above +5% YoY) and its late-stage pipeline yields 2-3 significant approvals (>$500M potential) over the next 18-24 months, then it could stabilize revenue around its $60B guidance range and see a modest re-rating to a 12-13x forward...
Full PFE AnalysisSummit Therapeutics presents a compelling, high-risk, high-reward investment opportunity driven by ivonescimab's potential to become a blockbuster drug in the massive 2nd-line EGFR mutant NSCLC market. With critical regulatory and clinical catalysts approaching in 2026, strong leadership, and a differentiated mechanism, the company is strategically positioned for significant growth, provided it na...
Full SMMT AnalysisPrice Targets & Strategy
Price Targets & Entry/Exit Strategy
Sign up free to unlock the full comparison
Growth Catalysts
Growth Catalysts Comparison
Sign up free to unlock the full comparison
Market Sentiment
Market Sentiment Analysis
Sign up free to unlock the full comparison
The Deep Dive
Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and Comirnaty contracts offer stability, but these are incremental gains for a company of Pfizer's scale....
Full PFE AnalysisSummit Therapeutics continues to hold significant 10x growth potential, primarily driven by its lead asset, ivonescimab, targeting the large US/EU non-small cell lung cancer (NSCLC) market. The bispecific mechanism provides a strong competitive advantage, and key regulatory milestones like the PDUFA date in November 2026 and HARMONi-3 interim data in Q2 2026 serve as major catalysts. The company maintains a robust cash position and positive free cash flow, supporting its clinical development. Ho...
Full SMMT AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.